HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets.
Mediocre balance sheet with limited growth.
Share Price & News
How has HLS Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HLS's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: HLS exceeded the Canadian Healthcare industry which returned -42.6% over the past year.
Return vs Market: HLS exceeded the Canadian Market which returned -21.2% over the past year.
Price Volatility Vs. Market
How volatile is HLS Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StWho Has Been Selling HLS Therapeutics Inc. (TSE:HLS) Shares?
2 months ago | Simply Wall StDo Institutions Own HLS Therapeutics Inc. (TSE:HLS) Shares?
3 months ago | Simply Wall StAre Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 39%?
Is HLS Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: HLS (CA$17.21) is trading above our estimate of fair value (CA$8.34)
Significantly Below Fair Value: HLS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: HLS is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.
PE vs Market: HLS is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HLS is good value based on its PB Ratio (2.1x) compared to the CA Healthcare industry average (2.1x).
How is HLS Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HLS's revenue (27.9% per year) is forecast to grow faster than the Canadian market (3.4% per year).
High Growth Revenue: HLS's revenue (27.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLS is forecast to be unprofitable in 3 years.
How has HLS Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HLS is currently unprofitable.
Growing Profit Margin: HLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HLS is unprofitable, and losses have increased over the past 5 years at a rate of -19.1% per year.
Accelerating Growth: Unable to compare HLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HLS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7%).
Return on Equity
High ROE: HLS has a negative Return on Equity (-10.97%), as it is currently unprofitable.
How is HLS Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: HLS's short term assets ($63.1M) exceed its short term liabilities ($47.1M).
Long Term Liabilities: HLS's short term assets ($63.1M) do not cover its long term liabilities ($94.3M).
Debt to Equity History and Analysis
Debt Level: HLS's debt to equity ratio (53%) is considered high.
Reducing Debt: Insufficient data to determine if HLS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HLS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HLS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 133.3% per year.
What is HLS Therapeutics's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: HLS's dividend (1.12%) isn’t notable compared to the bottom 25% of dividend payers in the Canadian market (2.57%).
High Dividend: HLS's dividend (1.12%) is low compared to the top 25% of dividend payers in the Canadian market (8.24%).
Stability and Growth of Payments
Stable Dividend: HLS is not paying a notable dividend for the Canadian market, therefore no need to check if payments are stable.
Growing Dividend: HLS is not paying a notable dividend for the Canadian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: HLS is not paying a notable dividend for the Canadian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HLS's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Greg Gubitz (62yo)
Mr. Gregory David Gubitz, also known as Greg, B.A., LL.B, is Co-Founder of HLS Therapeutics Inc. and serves as its Chief Executive Officer and Director. Mr. Gubitz serves as an Executive Officer for MDS, I ...
CEO Compensation Analysis
Compensation vs Market: Greg's total compensation ($USD1.22M) is about average for companies of similar size in the Canadian market ($USD1.19M).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
|Co-Founder & Executive Chairman||5.83yrs||US$907.12k||3% $16.4m|
|President & COO||6yrs||US$1.20m||2.87% $15.7m|
|Chief Financial Officer||1.58yrs||US$481.59k||0.069% $378.6k|
|Chief Commercial Officer||1.58yrs||US$658.52k||no data|
|General Counsel & Corporate Secretary||1.92yrs||no data||0.0016% $8.6k|
|Head of Corporate Strategy & Business Development||2.58yrs||no data||no data|
Experienced Management: HLS's management team is considered experienced (2.3 years average tenure).
|Co-Founder & Executive Chairman||5.83yrs||US$907.12k||3% $16.4m|
|Independent Director||1.25yrs||no data||no data|
|Lead Independent Director||no data||US$194.95k||no data|
|Independent Director||2.08yrs||US$54.15k||no data|
|Independent Director||4.67yrs||US$178.92k||no data|
|Independent Director||5.08yrs||US$54.82k||no data|
Experienced Board: HLS's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.
HLS Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
- Name: HLS Therapeutics Inc.
- Ticker: HLS
- Exchange: TSX
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: CA$546.216m
- Shares outstanding: 31.74m
- Website: https://www.hlstherapeutics.com
Number of Employees
- HLS Therapeutics Inc.
- 10 Carlson Court
- Suite 701
- M9W 6L2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HLS||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Mar 2018|
|HLTR.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Mar 2018|
HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It markets Clozaril, a pharmaceutical product used in the treatment of schizophrenia in Canada and the United States. The company also holds the U.S. marketing rights to Absorica, a commercial stage dermatology product. It has license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company is headquartered in Toronto, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/08 01:21|
|End of Day Share Price||2020/04/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.